Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers

Bernard A. Hunt, Michael B. Bottorff, Vanessa L. Herring, Timothy H. Self, Richard L. Lalonde

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Diltiazem and verapamil inhibit oxidative drug metabolism both in vivo and in vitro. We compared their effects on the stereoselective pharmacokinetics and protein binding of propranolol in 12 subjects. After 6 days of coadministration with racemic propranolol, diltiazem caused decreases of 27% and 24% in d‐propranolol and 1‐propranolol oral clearances, respectively (p < 0.05 versus control). With verapamil, d‐propranolol oral clearance decreased 32% (p < 0.05), and 1‐propranolol oral clearance decreased 26% (p < 0.05). The unbound fraction of d‐propranolol was higher than that of 1‐propranolol (p < 0.05), but the protein binding was not altered by diltiazem or verapamil. Both drugs therefore decreased the unbound oral clearance of each propranolol enantiomer (p < 0.05). Verapamil caused a stereoselective effect and increased the d/1 ratio of propranolol serum concentrations (p < 0.05) and decreased the d/1 ratio of oral clearance (p < 0.05). Clinical Pharmacology and Therapeutics (1990) 47, 584–591; doi:

Original languageEnglish (US)
Pages (from-to)584-591
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume47
Issue number5
DOIs
StatePublished - 1990

Fingerprint

Stereoisomerism
Calcium Channel Blockers
Verapamil
Propranolol
Diltiazem
Pharmacokinetics
Protein Binding
Clinical Pharmacology
Pharmaceutical Preparations
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers. / Hunt, Bernard A.; Bottorff, Michael B.; Herring, Vanessa L.; Self, Timothy H.; Lalonde, Richard L.

In: Clinical Pharmacology and Therapeutics, Vol. 47, No. 5, 1990, p. 584-591.

Research output: Contribution to journalArticle

Hunt, Bernard A. ; Bottorff, Michael B. ; Herring, Vanessa L. ; Self, Timothy H. ; Lalonde, Richard L. / Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers. In: Clinical Pharmacology and Therapeutics. 1990 ; Vol. 47, No. 5. pp. 584-591.
@article{32ff9bce35ae49f0bd423dcb110a99c8,
title = "Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers",
abstract = "Diltiazem and verapamil inhibit oxidative drug metabolism both in vivo and in vitro. We compared their effects on the stereoselective pharmacokinetics and protein binding of propranolol in 12 subjects. After 6 days of coadministration with racemic propranolol, diltiazem caused decreases of 27{\%} and 24{\%} in d‐propranolol and 1‐propranolol oral clearances, respectively (p < 0.05 versus control). With verapamil, d‐propranolol oral clearance decreased 32{\%} (p < 0.05), and 1‐propranolol oral clearance decreased 26{\%} (p < 0.05). The unbound fraction of d‐propranolol was higher than that of 1‐propranolol (p < 0.05), but the protein binding was not altered by diltiazem or verapamil. Both drugs therefore decreased the unbound oral clearance of each propranolol enantiomer (p < 0.05). Verapamil caused a stereoselective effect and increased the d/1 ratio of propranolol serum concentrations (p < 0.05) and decreased the d/1 ratio of oral clearance (p < 0.05). Clinical Pharmacology and Therapeutics (1990) 47, 584–591; doi:",
author = "Hunt, {Bernard A.} and Bottorff, {Michael B.} and Herring, {Vanessa L.} and Self, {Timothy H.} and Lalonde, {Richard L.}",
year = "1990",
doi = "10.1038/clpt.1990.79",
language = "English (US)",
volume = "47",
pages = "584--591",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers

AU - Hunt, Bernard A.

AU - Bottorff, Michael B.

AU - Herring, Vanessa L.

AU - Self, Timothy H.

AU - Lalonde, Richard L.

PY - 1990

Y1 - 1990

N2 - Diltiazem and verapamil inhibit oxidative drug metabolism both in vivo and in vitro. We compared their effects on the stereoselective pharmacokinetics and protein binding of propranolol in 12 subjects. After 6 days of coadministration with racemic propranolol, diltiazem caused decreases of 27% and 24% in d‐propranolol and 1‐propranolol oral clearances, respectively (p < 0.05 versus control). With verapamil, d‐propranolol oral clearance decreased 32% (p < 0.05), and 1‐propranolol oral clearance decreased 26% (p < 0.05). The unbound fraction of d‐propranolol was higher than that of 1‐propranolol (p < 0.05), but the protein binding was not altered by diltiazem or verapamil. Both drugs therefore decreased the unbound oral clearance of each propranolol enantiomer (p < 0.05). Verapamil caused a stereoselective effect and increased the d/1 ratio of propranolol serum concentrations (p < 0.05) and decreased the d/1 ratio of oral clearance (p < 0.05). Clinical Pharmacology and Therapeutics (1990) 47, 584–591; doi:

AB - Diltiazem and verapamil inhibit oxidative drug metabolism both in vivo and in vitro. We compared their effects on the stereoselective pharmacokinetics and protein binding of propranolol in 12 subjects. After 6 days of coadministration with racemic propranolol, diltiazem caused decreases of 27% and 24% in d‐propranolol and 1‐propranolol oral clearances, respectively (p < 0.05 versus control). With verapamil, d‐propranolol oral clearance decreased 32% (p < 0.05), and 1‐propranolol oral clearance decreased 26% (p < 0.05). The unbound fraction of d‐propranolol was higher than that of 1‐propranolol (p < 0.05), but the protein binding was not altered by diltiazem or verapamil. Both drugs therefore decreased the unbound oral clearance of each propranolol enantiomer (p < 0.05). Verapamil caused a stereoselective effect and increased the d/1 ratio of propranolol serum concentrations (p < 0.05) and decreased the d/1 ratio of oral clearance (p < 0.05). Clinical Pharmacology and Therapeutics (1990) 47, 584–591; doi:

UR - http://www.scopus.com/inward/record.url?scp=0025359380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025359380&partnerID=8YFLogxK

U2 - 10.1038/clpt.1990.79

DO - 10.1038/clpt.1990.79

M3 - Article

VL - 47

SP - 584

EP - 591

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -